|
【结 构 式】 
|
【分子编号】48090 【品名】sodium 2-[[(E)-2-(5-[[(6-[[(4R,7S,13S)-7-(3-[[amino(imino)methyl]amino]propyl)-13-(carboxymethyl)-4-isopropyl-6-methyl-2,5,8,11,14-pentaoxo-3,6,9,12,15-pentaazabicyclo[15.3.1]henicosa-1(21),17,19-trien-19-yl]amino]-6-oxohexyl)amino]carbonyl]-2-pyridinyl)hydrazono]methyl]benzenesulfonate 【CA登记号】 |
【 分 子 式 】C45H58N13NaO12S 【 分 子 量 】1028.091708 【元素组成】C 52.57% H 5.69% N 17.71% Na 2.24% O 18.67% S 3.12% |
合成路线1
该中间体在本合成路线中的序号：(IX)In order to stabilize the hydrazino compound (I), a stable hydrazone derivative was prepared by two alternative procedures. Condensation of 6-hydrazinonicotinic acid (IV) with sodium 2-formylbenzenesulfonate (V) gave the hydrazone acid (VI), which was further converted to the succinimidyl active ester (VII) by treatment with N-hydroxysuccinimide and DCC. Coupling of succinimidyl ester (VII) with the aminocaproyl cyclic peptide (VIII) then gave the target hydrazone derivative (IX). Alternatively, (IX) was also prepared by condensation of the hydrazino peptide (I) with sodium 2-formylbenzenesulfonate (V).
| 【1】 Harris, T.D.; et al.; Synthesis of stable hydrazones of a hydrazinonicotinyl-modified peptide for the preparation of 99mTc-labeled radiopharmaceuticals. Bioconjugate Chem 1999, 10, 5, 808. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 48084 | 2-[(5S,11S,14R)-11-(3-[[amino(imino)methyl]amino]propyl)-19-[(6-[[(6-hydrazino-3-pyridinyl)carbonyl]amino]hexanoyl)amino]-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazabicyclo[15.3.1]henicosa-1(21),17,19-trien-5-yl]acetic acid | C38H55N13O9 | 详情 | 详情 | |
| (IV) | 48085 | 6-hydrazinonicotinic acid | C6H7N3O2 | 详情 | 详情 | |
| (V) | 48086 | Benzaldehyde-2-sulfonic acid sodium; sodium 2-formylbenzenesulfonate | 1008-72-6 | C7H5NaO4S | 详情 | 详情 |
| (VI) | 48087 | sodium 2-[[(E)-2-(5-carboxy-2-pyridinyl)hydrazono]methyl]benzenesulfonate | C13H10N3NaO5S | 详情 | 详情 | |
| (VII) | 48088 | sodium 2-[[(E)-2-(5-[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]-2-pyridinyl)hydrazono]methyl]benzenesulfonate | C17H13N4NaO7S | 详情 | 详情 | |
| (VIII) | 48089 | 2-[(5S,11S,14R)-19-[(6-aminohexanoyl)amino]-11-(3-[[amino(imino)methyl]amino]propyl)-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazabicyclo[15.3.1]henicosa-1(21),17,19-trien-5-yl]acetic acid | C32H50N10O8 | 详情 | 详情 | |
| (IX) | 48090 | sodium 2-[[(E)-2-(5-[[(6-[[(4R,7S,13S)-7-(3-[[amino(imino)methyl]amino]propyl)-13-(carboxymethyl)-4-isopropyl-6-methyl-2,5,8,11,14-pentaoxo-3,6,9,12,15-pentaazabicyclo[15.3.1]henicosa-1(21),17,19-trien-19-yl]amino]-6-oxohexyl)amino]carbonyl]-2-pyridinyl)hydrazono]methyl]benzenesulfonate | C45H58N13NaO12S | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(IX)The title compound was then obtained by complexation of hydrazone (IX) with phosphine (II) and tricine (III) in the presence of Na99mTcO4 and SnCl2. Under these conditions, the hydrazone protecting group hydrolyzed to the required hydrazine. Some shortcomings caused by SnCl2 could be omitted using a non-SnCl2-containing formulation in the presence of mannitol and pluronic acid as surfactant agents.
| 【1】 Edwards, D.S.; et al.; 99mTc-Labeling of hydrazones of a hydrazinonicotinamide conjugated cyclic peptide. Bioconjugate Chem 1999, 10, 5, 803. |
| 【2】 Liu, S.; et al.; Towards developing A non-SnCl2 formulation for RP444, a new radiopharmaceutical for thrombus imaging. J Pharm Sci 2001, 90, 2, 114. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (II) | 37264 | trisodium 3-[bis(3-sulfonatophenyl)phosphino]benzenesulfonate | C18H12Na3O9PS3 | 详情 | 详情 | |
| (III) | 37265 | 4'-(hydroxymethyl)[1,1'-biphenyl]-2-carbonitrile | C14H11NO | 详情 | 详情 | |
| (IX) | 48090 | sodium 2-[[(E)-2-(5-[[(6-[[(4R,7S,13S)-7-(3-[[amino(imino)methyl]amino]propyl)-13-(carboxymethyl)-4-isopropyl-6-methyl-2,5,8,11,14-pentaoxo-3,6,9,12,15-pentaazabicyclo[15.3.1]henicosa-1(21),17,19-trien-19-yl]amino]-6-oxohexyl)amino]carbonyl]-2-pyridinyl)hydrazono]methyl]benzenesulfonate | C45H58N13NaO12S | 详情 | 详情 |